Table C.1.
FL‐no | Chemical Name | Test System in vitro | Test Object | Concentrations of Substance and Test Conditions | Result | Reference | Comments |
---|---|---|---|---|---|---|---|
07.101 | 4‐Methylpent‐3‐en‐2‐one | Reverse mutation |
Salmonella Typhimurium TA98, TA100, TA102, TA1535 and TA1537 |
1.6–5,000 μg/platea | Negative | Williams (2009) | Valid. Study design complies with current recommendations |
156.25–5,000 μg/platea , b | Negative | ||||||
Micronucleus assay | Human peripheral blood lymphocytes | 600–981.4 μg/mLc | Negative | Stone (2011) |
Valid Complies with OECD Guideline 487 |
||
200–981.4 μg/mLd | Negative | ||||||
100–500 μg/mLd | Negative | ||||||
100–300 μg/mLe | Negative | ||||||
07.177 | 7‐methyl‐3‐octenone‐2 | Reverse mutation |
S. Typhimurium TA102 |
1.6–5,000 μg/platea | Negative | Ballantyne (2011) | Valid. Studies combined comply with current recommendations |
51.2–5,000 μg/platea , b | Negative | ||||||
S. Typhimurium TA98, TA100, TA1535, TA1537, and TA1538 |
15–5,000 μg/platea | Negative | Thompson (1996) | ||||
Micronucleus assay | Human peripheral Blood lymphocytes | 5–15 μg/mLc | Equivocal | Lloyd (2009) |
Valid Testing strategies including FISH analyses for determination of potential clastogenicity or aneugenicity. The study complies with OECD Guideline 487 |
||
30–60 μg/mLd | Equivocal | ||||||
2–6 μg/mLe | Positive | ||||||
5.5–8 μg/mLe | Positive | Lloyd (2010) |
FGE: Flavouring Group Evaluation; FL‐no: FLAVIS number; FLAVIS: Flavour Information System; OECD: Organisation for Economic Co‐operation and Development; FISH: Fluorescence in situ hybridisation.
With and without S9‐mix metabolic activation.
Assay modified with pre‐incubation in the presence of S9‐mix.
Without metabolic activation, 3 h treatment + 21 h recovery.
With metabolic activation, 3 h treatment + 21 h recovery.
Without metabolic activation, 24 h + 0 h recovery.
Validity of genotoxicity studies:
Valid.
Limited validity (e.g. if certain aspects are not in accordance with OECD Guidelines or current standards and/or limited documentation).
Insufficient validity (e.g. if main aspects are not in accordance with any recognised guidelines (e.g. OECD) or current standards inappropriate/not validated test system).
Validity cannot be evaluated (e.g. insufficient documentation, short abstract only, too little experimental details provided, text not in a Community language).